However, tissue plasminogen activator (tPA) remains the only effective drug approved by the United States Food and Drug Administration (FDA) for acute ischemic stroke while the narrow time window restricts its application to only a limited number of stroke patients [5, 6]. This evidence concerns the gene PLAT and Stroke.